None
Quote | Sierra Oncology Inc. (NASDAQ:SRRA)
Last: | $54.99 |
---|---|
Change Percent: | 0.04% |
Open: | $54.98 |
Close: | $54.99 |
High: | $55.17 |
Low: | $54.98 |
Volume: | 862,822 |
Last Trade Date Time: | 06/30/2022 04:39:17 am |
News | Sierra Oncology Inc. (NASDAQ:SRRA)
Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEO John Nicols to retire after ten years leading the transformation and growth of Codexis REDWOOD CITY, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading en...
Zendesk to be acquired by an investor group led by investment firms Permira and Hellman & Friedman in an all-cash transaction valued at approximately $10.2 billion. The price that Zendesk finally settled for was 40% below the midpoint of the original offer made by the same group o...
Message Board Posts | Sierra Oncology Inc. (NASDAQ:SRRA)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $SRRA News Article - Why Is Creatd (CRTD) Stock Up Today? | whytestocks | investorshangout | 04/13/2022 4:55:52 PM |
whytestocks: $SRRA News Article - Dear KLDO Stock Fans, Mark Your Calendars for April 28 | whytestocks | investorshangout | 04/13/2022 4:30:52 PM |
whytestocks: $SRRA News Article - Lifshitz Law PLLC Announces Investigation of CDK, SAIL, SRRA, and | whytestocks | investorshangout | 04/13/2022 2:50:49 PM |
whytestocks: $SRRA News Article - Sierra Oncology Inc.: 52-Week High Recently Eclipsed (SRRA) | whytestocks | investorshangout | 03/17/2022 4:50:56 PM |
whytestocks: $SRRA News Article - Shares of Sierra Oncology Inc. (SRRA) Rise Above Previous 52-Week | whytestocks | investorshangout | 02/07/2022 5:10:53 PM |
News, Short Squeeze, Breakout and More Instantly...
Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEO John Nicols to retire after ten years leading the transformation and growth of Codexis REDWOOD CITY, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading en...
– Submission seeks approval of momelotinib for the treatment of myelofibrosis – Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced the company has submi...